首页> 美国卫生研究院文献>other >Lactobacillus Rhamnosus GG Treatment Improves Intestinal Permeability and Modulates Inflammatory Response and Homeostasis of Spleen and Colon in Experimental Model of Pseudomonas Aeruginosa Pneumonia
【2h】

Lactobacillus Rhamnosus GG Treatment Improves Intestinal Permeability and Modulates Inflammatory Response and Homeostasis of Spleen and Colon in Experimental Model of Pseudomonas Aeruginosa Pneumonia

机译:鼠李糖乳杆菌GG治疗可改善肠通透性并调节铜绿假单胞菌肺炎实验模型的脾脏和结肠的炎症反应和体内稳态。

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Background and AimsRecent clinical trials and in vivo models demonstrate probiotic administration can reduce occurrence and improve outcome of pneumonia and sepsis, both major clinical challenges worldwide. Potential probiotic benefits include maintenance of gut epithelial barrier homeostasis and prevention of downstream organ dysfunction due to systemic inflammation. However, mechanism(s) of probiotic-mediated protection against pneumonia remain poorly understood. This study evaluated potential mechanistic targets in the maintenance of gut barrier homeostasis following Lactobacillus rhamnosus GG (LGG) treatment in a mouse model of pneumonia.
机译:背景和目标最近的临床试验和体内模型表明,益生菌的施用可以减少肺炎和败血症的发生并改善肺炎和败血症的发生,这是全球范围内的主要临床挑战。潜在的益生菌益处包括维持肠道上皮屏障稳态和预防由于全身性炎症引起的下游器官功能障碍。然而,益生菌介导的抗肺炎保护机制尚不清楚。这项研究评估了鼠李糖乳杆菌GG(LGG)治疗后在肺炎小鼠模型中维持肠屏障稳态的潜在机制目标。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号